Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIX1 in Recurrent or Progressive High-grade Glioma
NCT07464925Phase 1Recruiting
- Sponsor
- Tetragon Biosciences
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glix1 in glioma and glioblastoma (GBM), sponsored by Tetragon Biosciences. Primary endpoints: Treatment-emergent Adverse Events and Maximal Tolerated Dose and/or Recommended Dose at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
glix1
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT07464925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464925.